Practice Sale & Expansion Spoke · Concept Guide · 2026

The ABA practice due diligence playbook: what buyers and sellers examine

Due diligence in an ABA deal is mostly state-neutral: the same nine workstreams, revenue, compliance, people, and clinical model, drive value and risk in almost every transaction. This playbook walks through each, what it screens for, and how it shapes price and protections. The state-specific overlays, licensing, change of ownership, non-competes, and records, live on each state's transaction page.

Important · This is not legal, tax, or financial advice

This page is general educational information about the diligence workstreams that commonly arise when ABA practices are bought, sold, or invested in. It is not legal, tax, accounting, or financial advice, it is not a valuation or a recommendation, it does not create an attorney-client relationship, and it is not a substitute for advice from qualified transaction counsel, healthcare regulatory counsel, a quality-of-earnings provider, a tax advisor, and a financial advisor. Diligence scope, deal terms, and risk allocation change and turn on the specific facts of a transaction and the law of the relevant state. Verify current requirements and engage qualified professionals before relying on anything here.

⚖️
The diligence thesis
ABA practices are unusual diligence targets because their value rests on three fragile pillars: payer relationships that are heavily Medicaid and managed-care dependent, a workforce of certified and licensed clinicians whose credentials and classification carry compliance risk, and a clinical model whose documentation must support medical necessity. Most of the value, and most of the risk, sits in those pillars rather than in hard assets. As consolidation has matured, buyers have shifted from growth-at-any-cost to a flight to quality, scrutinizing the clinical model, the payer mix, the audit history, and the documentation far more closely than a few years ago. The result is a diligence process that is bidirectional: buyers run it to price and protect against risk, and sophisticated sellers run it on themselves first to fix problems, support the valuation, and avoid surprises that erode price late in a deal. This playbook organizes that process into nine workstreams that recur in nearly every ABA transaction, regardless of state.

The workstreams below are state-neutral. Each state's transaction page carries a short diligence-flags section that adds the local overlays, the change-of-ownership route, license and certification transfer, non-compete enforceability, Medicaid revalidation, and records custody, that sit on top of this common core. Read this playbook for the shared mechanics, then the relevant state page for the local specifics.

What diligence screens
Revenue, compliance, people, model
Highest-risk area
Medicaid audit and recoupment
Most scrutinized lately
Clinical model and payer mix
Runs both ways
Buy-side and sell-side

Revenue cycle and payer mix

The first workstream is the quality and durability of revenue. A buyer examines the accounts-receivable aging, the denial and rework rate, the clean-claim and collection percentages, and the trend in net revenue per authorized hour, because ABA revenue is claims-based and sensitive to documentation and authorization. The payer mix is examined alongside the cash: a practice that is overwhelmingly Medicaid or dependent on one managed-care plan has a different risk profile than a diversified one, and the rate environment in the relevant state, which can move sharply, bears directly on forward revenue. Sellers strengthen this workstream by cleaning up the revenue-cycle metrics and documenting the payer mix before going to market, so the earnings the valuation rests on are defensible.

Medicaid and insurance audit and recoupment exposure

This is the workstream most likely to break or reprice an ABA deal. Because ABA is heavily Medicaid-funded and documentation-intensive, payers can audit past claims and recoup overpayments years after the fact, so a buyer examines the practice's audit history, any open or threatened audits, prior recoupments, corrective-action plans, and exclusion or sanction history. The central question is contingent liability: if a payer later determines that past claims were not adequately documented or medically necessary, who bears the recoupment. This is why the compliance representation, the seller's contractual statement that it has billed in compliance with payer rules, and the related indemnification are so heavily negotiated. A clean audit history supports price; a history of recoupments, or thin documentation that invites them, pushes risk into escrow, holdbacks, or a lower price.

Clinical credentialing verification

ABA delivery depends on properly credentialed people, so a buyer verifies the certification and licensure of the clinical workforce: the behavior analysts' national certification and, where the state requires it, individual licensure; the assistant analysts' and technicians' credentials; supervision ratios and documentation; and any lapses, disciplinary actions, or gaps that could affect billing or expose the practice. Because in most states the clinical license or credential follows the individual rather than the entity, the buyer confirms that the people who generate the revenue are properly credentialed and will remain so, and that Medicaid and payer enrollment reflect the correct rendering and supervising providers. Credential gaps are both a compliance risk and a revenue risk, since claims tied to improperly credentialed providers can be denied or recouped.

Authorization and documentation integrity

Authorization and documentation are where medical necessity is proven, and they are examined together. A buyer reviews whether services were properly prior-authorized, whether assessments and treatment plans support the authorized hours, whether session notes and data substantiate the billed services, and whether reauthorization timelines were met. Gaps here, services delivered beyond authorization, treatment plans that do not justify the intensity billed, or notes that do not match claims, are the raw material of a future recoupment, so documentation integrity ties directly back to the audit workstream. Sellers improve this workstream by auditing their own documentation before a sale and remediating gaps, since strong documentation both supports the valuation and reduces the contingent liability a buyer prices in.

Worker classification

ABA practices often engage clinicians as independent contractors, which creates worker-classification exposure that a buyer examines closely. The question is whether behavior analysts or technicians treated as 1099 contractors should, under federal and state tests, be employees, because misclassification can create liability for back taxes, wage-and-hour claims, and benefits, and can complicate supervision and billing requirements. A buyer reviews the classification of the workforce, the contracts, and the degree of control exercised, and weighs the cost of reclassification into the model. This workstream interacts with state non-compete and wage law, which is why the per-state pages address how covenants and wage thresholds apply to differently classified staff.

Payer concentration and contract risk

Concentration risk is examined on both the payer and the referral side. A practice that depends on a single managed-care plan, a single Medicaid contract, or a narrow referral network is more fragile than a diversified one, because the loss or repricing of one relationship can impair the business. The buyer also examines the payer contracts themselves for assignability and change-of-ownership provisions, since some contracts require consent to assign or treat a change of control as a terminating or re-credentialing event, which bears directly on whether an equity or an asset structure preserves the revenue. Contract assignability is a recurring reason equity structures are cleaner than asset structures, a theme the per-state pages develop.

Owner-operator and key-person dependence

Many ABA practices are built around a founding clinician whose relationships, clinical leadership, and credential anchor the business, so a buyer examines how dependent the practice is on that person and on a few key staff. If the owner-operator is also the clinical director, the supervising analyst on key cases, and the main referral relationship, their departure can impair both compliance and revenue, so the deal often includes a transition period, a retained role, an earnout tied to continued involvement, and carefully structured restrictive covenants where the state allows them. Sellers reduce this risk, and support price, by building clinical leadership beneath the founder before a sale, so the business is not synonymous with one person.

Medical necessity and utilization screening

The flight to quality has put the clinical model itself under the microscope. A buyer screens whether the practice's utilization reflects individualized medical necessity or a tendency toward maximum billable hours, because a model that bills near the authorization ceiling regardless of clinical need is both a compliance risk and a sign of revenue that may not survive payer scrutiny or a clinical-quality review. The buyer examines treatment intensity relative to assessed need, outcome measurement, supervision quality, and whether the clinical documentation tells a coherent medical-necessity story. A defensible, individualized clinical model supports value; a model that looks like utilization maximization is discounted and pushes risk into the audit and documentation workstreams.

Deal protections that allocate residual risk

Diligence rarely eliminates risk; it surfaces and prices it, and the deal structure then allocates the residue. A buyer typically commissions a quality-of-earnings analysis to validate the financial picture, and the parties use a familiar toolkit to allocate risk: escrow and holdbacks to back the compliance and other representations, earnouts to bridge valuation gaps and align the seller through a transition, working-capital adjustments, detailed representations and warranties with indemnification, and, increasingly, representations-and-warranties insurance to cover breaches. The compliance representation and its indemnity are usually the most negotiated, given the recoupment exposure. How aggressively these protections are used tracks what diligence finds: clean diligence supports a simpler structure and a higher price, while unresolved risk drives larger escrows, longer survival periods, and price adjustments.

Diligence does not remove risk; it finds it, prices it, and lets the deal structure allocate it. In ABA, the risk that matters most is whether past revenue would survive a payer looking back.

How a buyer sequences diligence

  1. Start with revenue and payer mix. Build the picture of where revenue comes from, how durable it is, and how concentrated it is, since everything else is read against it.
  2. Test compliance and audit exposure early. Audit history, recoupments, and documentation quality are deal-defining, so surface them before investing in the rest.
  3. Verify the people. Confirm clinician credentialing, supervision, and worker classification, which underpin both compliance and revenue.
  4. Probe the clinical model. Screen utilization against medical necessity to judge whether the revenue is clinically defensible.
  5. Map contracts and key-person risk. Examine payer-contract assignability and dependence on the owner-operator, which shape structure and transition terms.
  6. Allocate the residue. Use the quality-of-earnings analysis and the protection toolkit, escrow, earnouts, representations, and insurance, to allocate what diligence could not eliminate.

Common ABA diligence red flags

Red flagWhat it signalsTypical deal impact
History of payer recoupments or open auditsPast billing may not survive scrutiny; contingent liabilityLarger escrow or holdback, stronger compliance indemnity, price adjustment
Thin or inconsistent documentationMedical necessity for billed services is not well supportedRecoupment risk priced in; documentation remediation before close
Utilization near the authorization ceiling across clientsPossible maximum-billable-hours model rather than individualized needClinical-quality discount; deeper audit and necessity review
Heavy single-payer or single-MCO concentrationRevenue fragile to one relationship or rate changeValuation discount; earnout or contingency tied to retention
Clinicians engaged as 1099 contractorsWorker-misclassification exposureReclassification cost modeled; indemnity for back liability
Business dependent on the founding clinicianKey-person risk to compliance and revenueTransition period, retained role, earnout, covenants where allowed
Credentialing gaps or lapsesClaims tied to improperly credentialed providersDenial and recoupment risk; remediation as a closing condition
Payer contracts requiring consent to assignAsset structure may not preserve revenueStructure shifts toward equity; consents sought before close

How this connects to the rest of the guide

This playbook is the shared core; the rest of the spoke adds the surrounding structure:

  • The other concept pages. Deal structures and economics covers how asset, equity, and recapitalization choices and the protection toolkit fit together; private equity in ABA covers the investment lifecycle and regulatory backdrop; multistate expansion covers entering new states; and winding down covers closure and continuity.
  • The per-state transaction pages. Each state's page in the Practice Sale and Expansion spoke carries a diligence-flags section that layers the local overlays, change of ownership, license and certification transfer, non-compete enforceability, Medicaid revalidation, and records custody, onto this common core.
  • The compliance spokes. The substance a buyer diligences, ownership rules, entity structure, licensing, Medicaid and insurance mandates, and facility licensure and records, is detailed across the rest of the ABA compliance guide.

Frequently asked questions

What is the single biggest diligence risk in an ABA deal?
Usually audit and recoupment exposure. Because ABA is heavily Medicaid-funded and documentation-intensive, payers can look back and recoup overpayments, so the buyer's central question is whether past revenue would survive scrutiny. That is why the compliance representation and its indemnity are so heavily negotiated.
Why do buyers scrutinize the clinical model now?
Because the market has shifted to a flight to quality. Buyers screen whether utilization reflects individualized medical necessity or a maximum-billable-hours pattern, since a model that bills near the ceiling regardless of need is both a compliance risk and a sign of revenue that may not survive payer or clinical-quality review.
Should a seller run diligence on itself?
Sophisticated sellers do. Sell-side diligence lets a seller fix documentation, credentialing, and classification problems, support the valuation, and avoid late surprises that erode price. Diligence runs both ways; a seller who has done its own homework negotiates from a stronger position.
How does diligence affect the deal structure?
Directly. Clean diligence supports a simpler structure and a higher price; unresolved risk drives larger escrows, longer representation-survival periods, earnouts, and price adjustments. Findings about payer-contract assignability and credentialing also push deals toward equity structures, which often preserve enrollment and contracts more cleanly than asset deals.
Is worker classification really a deal issue?
Yes. Many ABA practices use 1099 contractors, and if clinicians should be employees under federal and state tests, the practice faces back-tax, wage-and-hour, and benefits exposure, plus supervision and billing complications. Buyers model the cost of reclassification and often seek indemnity for past liability.

Where professional advice is essential, not optional

Diligence is a team exercise. A buyer or seller works with transaction counsel, healthcare regulatory counsel, a quality-of-earnings provider, a tax advisor, and a financial advisor to run these workstreams, interpret the findings, and translate them into price and protections, layering the relevant state's overlays onto this common core. This playbook is an orientation to the workstreams, not a substitute for that team, and nothing here is legal, tax, or financial advice.

The practical sequence is to build the revenue and payer picture, test compliance and audit exposure early, verify the people, probe the clinical model, map contract and key-person risk, and allocate the residue with the protection toolkit, then read the relevant state transaction page for the local change-of-ownership, license, non-compete, Medicaid, and records overlays.

Confirm current requirements directly

This playbook describes diligence workstreams and deal mechanics that change and depend on the specific facts of a transaction and the law of the relevant state. Qualified transaction counsel, healthcare regulatory counsel, and financial and tax advisors are the authoritative sources. Neither this page nor any secondary source should be relied on in place of direct verification and professional advice.

Last updated June 2026. This is a state-neutral concept guide in the Practice Sale and Expansion spoke; the per-state transaction pages carry the local change-of-ownership, licensing, non-compete, Medicaid, and records overlays. Diligence scope, deal terms, and risk allocation change and depend on the specific facts of a transaction. Nothing here is legal, tax, or financial advice. Consult qualified transaction counsel, healthcare regulatory counsel, and financial and tax advisors before relying on this information.